North Shore Pediatric Therapy in Chicago Joins BlinkLab’s US Registrational Study

BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”), an innovative digital healthcare company developing AI-powered smartphone technology to transform the autism and ADHD diagnostic markets, is pleased to announce that North Shore Pediatric Therapy (“NSPT”) is joining our US clinical study. NSPT is the second US-based site to on-board for the 100-patient initial phase of the registrational study. Enrolment from the NSPT-site is expected to commence in the coming weeks.

• US-based North Shore Pediatric Therapy (“NSPT”) is the second clinical site to join BlinkLab’s registrational study.
  
• Located in the Chicago area, NSPT is a recognized leader in early autism intervention services, specializing in Applied Behavior Analysis (ABA), neuropsychology, speech therapy, occupational therapy, and mental health support.
• The NSPT clinical trial site is set to begin patient recruitment and diagnostic testing in the coming weeks, supporting timely and efficient data collection for the study.
• Together, with PriMED Clinical Research, these two leading US-based autism centers provide access to a large pool of diverse subjects that will accelerate the recruitment process and ensure high-quality data collection.

NSPT was selected for this study due to its extensive expertise in administering the ADOS-2 diagnostic tool, which is widely recognized as the gold standard for autism diagnosis. Their experienced neuropsychology team specializes in conducting comprehensive, play-based assessments that evaluate social, emotional, and communication behaviors, ensuring precise and reliable autism diagnoses. As part of our US registrational study, NSPT’s use of the ADOS-2 will serve as a critical benchmark for standard-of-care comparisons, helping validate the effectiveness of our Blinklab Dx 1 test.

In addition to their clinical expertise, NSPT provides access to a diverse population of children throughout the Chicago area, which is an essential factor in ensuring the study reflects a broad range of backgrounds and developmental profiles. Their ability to recruit children as young as 18 months old is particularly valuable for the BlinkLab study, as our mission is to enable early diagnosis and improve long-term outcomes for children with autism. With a strong track record in early intervention and autism diagnostics, NSPT’s participation enhances the study’s robustness, credibility, and real-world applicability, ultimately contributing to the advancement of Blinklab’s more accurate and accessible autism screening tool.

Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.